Aspirin and cancer: Has aspirin been overlooked as an adjuvant therapy

British Journal of Cancer

Volumn 105, Issue 8, 2011, Pages 1107-1113

  Langley, R E ^a   Burdett, S ^a   Tierney, J F ^a   Cafferty, F ^a   Parmar, M K B ^a   Venning, G ^b  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b Pharmaceutical Research Services   (United Kingdom)

Author keywords

aspirin; cyclooxygenase inhibition; randomised trials

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LYSINE ACETYLSALICYLATE; PLACEBO; ROFECOXIB;

ADJUVANT THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLEEDING; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG BINDING; DRUG HALF LIFE; DRUG SAFETY; ENZYME INHIBITION; ESOPHAGUS CANCER; HUMAN; INTESTINE CANCER; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG SMALL CELL CANCER; NEOPLASM; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN CANCER; STOMACH CANCER; TREATMENT RESPONSE;

ANTICARCINOGENIC AGENTS; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; NEOPLASMS;

EID: 80053994835     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.289     Document Type: Review

References (48)

1. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899 (Pubitemid 36297997)
2. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125: 328-336 (Pubitemid 36929412)
3. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM (2006) Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 20: 2009-2016 (Pubitemid 44953901)
4. Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17: 871-888 (Pubitemid 44081706)
5. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102 (Pubitemid 40365350)
6. Cha YI, DuBois RN (2007) NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58: 239-252 (Pubitemid 46706512)
7. Chan AO, Jim MH, Lam KF, Morris JS, Siu DC, Tong T, Ng FH, Wong SY, Hui WM, Chan CK, Lai KC, Cheung TK, Chan P, Wong G, Yuen MF, Lau YK, Lee S, Szeto ML, Wong BC, Lam SK (2007) Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 298: 1412-1419 (Pubitemid 47481607)
8. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294: 914-923 (Pubitemid 41215460)
9. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS (2008) Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134: 21-28 (Pubitemid 350309311)
10. Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649-658
11. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60: 4705-4708
12. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101: 256-266
13. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294: 47-55 (Pubitemid 41002838)
14. Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA, Buroker TR, Geeraerts LH, Veeder MH, Gesme, DH, Homburger HA (1991) A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 9: 2104-2109
15. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10: 501-507
16. Easty GC, Easty DM (1976) Prostaglandins and cancer. Cancer Treat Rev 3: 217-225 (Pubitemid 8007020)
17. Elder DJ, Paraskeva C (1999) Induced apoptosis in the prevention of colorectal cancer by non-steroidal anti-inflammatory drugs. Apoptosis 4: 365-372
18. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373: 1301-1309
19. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613 (Pubitemid 46710123)
20. Gasic GJ, Gasic TB, Murphy S (1972) Anti-metastatic effect of aspirin. Lancet 2: 932-933
21. Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61: 46-52
22. Grosch S, Maier TJ, Schiffmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98: 736-747 (Pubitemid 43983297)
23. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467-1472
24. Honn KV, Tang DG, Crissman JD (1992) Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 11: 325-351
25. Jankowski JA, Anderson M (2004) Review article: management of oesophageal adenocarcinoma-control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. Aliment Pharmacol Ther 20: 71-80; discussion 95-96 (Pubitemid 39424912)
26. Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959
27. Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399-4404
28. Langenbach R, Loftin CD, Lee C, Tiano H (1999) Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann N Y Acad Sci 889: 52-61 (Pubitemid 30040425)
29. Lebeau B, Chastang C, Muir JF, Vincent J, Massin F, Fabre C, The "Petites Cellules" Group (1993) No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. Cancer 71: 1741-1745 (Pubitemid 23067389)
30. Levine L (1981) Arachidonic acid transformation and tumor production. Adv Cancer Res 35: 49-79
31. Lipton A, Scialla S, Harvey H, Dixon R, Gordon R, Hamilton R, Ramsey H, Weltz M, Heckard R, White D (1982) Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. J Med 13: 419-429 (Pubitemid 13128400)
32. Logan RFA, Grainge MJ, Shepherd VC, Armintage NC, Muir KR, on behalf of the ukCAP Trial Group (2008) Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134: 29-38 (Pubitemid 350309319)
33. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, Guo Y, Boorman D, Einspahr J, Alberts DS, Gerner EW (2003) Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA 100: 7859-7864 (Pubitemid 36760060)
34. Patrono C, Patrignani P, Garcia Rodriguez LA (2001) Cyclooxygenase- selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108: 7-13 (Pubitemid 32634915)
35. Peterson HI (1983) Effects of prostaglandin synthesis inhibitors on tumor growth and vascularization. Experimental studies in the rat. Invasion Metastasis 3: 151-159 (Pubitemid 13018985)
36. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukcu R (1997b) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57: 2909-2915 (Pubitemid 27315038)
37. Powles TJ, Clark SA, Easty DM, Easty GC, Neville AM (1973) The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer 28: 316-321
38. Pyrko P, Soriano N, Kardosh A, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen CS, Chen TC, Schonthal AH (2006) Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2- inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 5: 19
39. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31-41
40. Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741-1750
41. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890 (Pubitemid 36297996)
42. Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387-437 (Pubitemid 39096597)
43. Stark LA, Reid K, Sansom OJ, Din FV, Guichard S, Mayer I, Jodrell DI, Clarke AR, Dunlop MG (2007) Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis 28: 968-976 (Pubitemid 47072180)
44. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH (1998) Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128: 713-720 (Pubitemid 28204862)
45. Takeda H, Sonoshita M, Oshima H, Sugihara K, Chulada PC, Langenbach R, Oshima M, Taketo MM (2003) Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 63: 4872-4877 (Pubitemid 37022619)
46. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R (2002) Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62: 3395-3401 (Pubitemid 34651385)
47. Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6: 130-140 (Pubitemid 43361545)
48. Zhang X, Morham SG, Langenbach R, Young DA (1999) Malignant transformation and antineoplastic actions of nonsteroidal antiinflamma-tory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190: 451-459 (Pubitemid 29395373)